110 related articles for article (PubMed ID: 25965753)
1. Biotech's wellspring--a survey of the health of the private sector in 2014.
Huggett B
Nat Biotechnol; 2015 May; 33(5):470-7. PubMed ID: 25965753
[No Abstract] [Full Text] [Related]
2. Biotech's wellspring: the health of private biotech in 2012.
Huggett B
Nat Biotechnol; 2013 May; 31(5):396-403. PubMed ID: 23657390
[No Abstract] [Full Text] [Related]
3. Biotech's wellspring-a survey of the health of the private sector in 2016.
Lawrence S
Nat Biotechnol; 2017 May; 35(5):413-420. PubMed ID: 28486451
[No Abstract] [Full Text] [Related]
4. Public sector seeks to bridge 'valley of death'.
Moran N
Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
[No Abstract] [Full Text] [Related]
5. Biotech's wellspring-a survey of the health of the private sector in 2015.
Huggett B
Nat Biotechnol; 2016 Jun; 34(6):608-15. PubMed ID: 27281417
[No Abstract] [Full Text] [Related]
6. Biotech's wellspring: a survey of the health of the private sector.
Huggett B
Nat Biotechnol; 2012 May; 30(5):395-400. PubMed ID: 22565961
[No Abstract] [Full Text] [Related]
7. Biotech's wellspring: the health of private biotech in 2013.
Huggett B
Nat Biotechnol; 2014 May; 32(5):428-35. PubMed ID: 24811512
[No Abstract] [Full Text] [Related]
8. Genentech grapples with direct offer.
Huggett B
Nat Biotechnol; 2009 Mar; 27(3):212. PubMed ID: 19270652
[No Abstract] [Full Text] [Related]
9. Public biotech 2007--the numbers.
Lawrence S; Lähteenmäki R
Nat Biotechnol; 2008 Jul; 26(7):753-62. PubMed ID: 18612294
[TBL] [Abstract][Full Text] [Related]
10. IPOs: the narrow window closes?
Lawrence S
Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
[No Abstract] [Full Text] [Related]
11. Trends in biopharmaceutical IPOS: 1996-2005.
Williams DR; Young CC
J Health Care Finance; 2006; 33(2):39-54. PubMed ID: 19175239
[TBL] [Abstract][Full Text] [Related]
12. When times get tough.
Jong S
Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
[No Abstract] [Full Text] [Related]
13. Eurofile. Private-public drive to cut delays in drug development.
Mundell I
Eur J Cancer; 2008 Jan; 44(2):169. PubMed ID: 18335586
[No Abstract] [Full Text] [Related]
14. Can public financing of the private sector defeat antimicrobial resistance?
James JE
J Public Health (Oxf); 2019 Jun; 41(2):422-426. PubMed ID: 29982521
[TBL] [Abstract][Full Text] [Related]
15. Crystal gazing: biotech's financial outlook: the biotech analyst's view.
Schmidt E
Nat Biotechnol; 2006 Mar; 24(3):261-2. PubMed ID: 16525376
[No Abstract] [Full Text] [Related]
16. Lack of private financing hobbles emerging biotech regions.
Jia H; Jayarama KS; Astvatsaturyan M
Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
[No Abstract] [Full Text] [Related]
17. AIDS and the private sector.
Nature; 2006 Oct; 443(7113):723. PubMed ID: 17051166
[No Abstract] [Full Text] [Related]
18. Back to irrational exuberance.
Laster L
Hosp Pract (1995); 2001 Jul; 36(7):9-10. PubMed ID: 11446602
[No Abstract] [Full Text] [Related]
19. Venture capital, control rights, and family enterprise growth.
Pang X; Liu L
PLoS One; 2021; 16(8):e0256318. PubMed ID: 34407119
[TBL] [Abstract][Full Text] [Related]
20. Public companies get creative in raising finance.
Hodgson J
Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
[No Abstract] [Full Text] [Related]
[Next] [New Search]
